Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis
혈액투석 환자에서 SARS-CoV-2 mRNA 백신의 세포 및 체액 면역원성
Article
[키워드] ACE2-RBD
addressed
Alpha
anti-SARS-CoV-2 IgG
Beta
binding
BNT162b2
cellular
Cellular immune response
cellular immune responses
Cluster
COVID-19
cytokine
detectable
dialysis
diminished
Efficacy
elicited
Epsilon
Follow-up
Haemodialysis
Horizon
humoral
Humoral and cellular immune responses
humoral immune response
humoral immune responses
humoral immunogenicity
immune responses
Immunity
Immunocompromised
immunogenicity
Immunoglobulin
immunoglobulins
increased risk
individual
initiative
interferon
interferon γ
Longevity
Mortality
mRNA vaccination
mRNA vaccine
multiplex
networking
neutralization
of BNT162b2
Patient
peptides
plasma
protective immunity
renal
renal insufficiency
Research
response
Saliva
SARS-CoV-2
SARS-CoV-2 spike peptide
SARS-CoV-2 vaccine
SARS-CoV-2 variant
serum
significantly
state
Stimulation
T-cell
Tourism
two-dose regimen
vaccination
Vaccine
vaccine responses
variants
variants of concern
Virus neutralization
was reduced
[DOI] 10.1016/j.ebiom.2021.103524 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.ebiom.2021.103524 PMC 바로가기 [Article Type] Article